Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients

Journal of Neurology

Volumn 260, Issue 1, 2013, Pages 122-130

  Heo, Sung Hyuk ^a   Lee, Ji Sung ^b   Kim, Beom Joon ^c   Hwang, Kyoung Jin ^a   Kim, Jun Hyun ^a   Chang, Dae Il ^a  

^a Kyung Hee University College of Medicine   (South Korea)

^b Korea University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Atherosclerosis; Carotid intima media thickness; Cilostazol; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; TRIFLUSAL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BRAIN ISCHEMIA; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, HDL; DISEASE PROGRESSION; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHODIESTERASE 3 INHIBITORS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STROKE; TETRAZOLES;

EID: 84872339812     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6599-y     Document Type: Article

References (34)

1. Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS (2010) Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels 26:502-510
2. Aizawa T, Wei H, Miano JM, Abe J, Berk BC, Yan C (2003) Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 93:406-413
3. Amarenco P, Labreuche J, Lavallee P, Touboul PJ (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35:2902-2909
4. Austin PC, Grootendorst P, Anderson GM (2007) A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 26:734-753
5. Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, Goto S, Rother J, Steg PG, Hirsch AT (2009) Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the reduction of atherothrombosis for continued health (REACH) registry. Atherosclerosis 204:e86-e92
6. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, Rosamond WD, Evans G (2000) Carotid wall thickness is predictive of incident clinical stroke: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol 151:478-487
7. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI (2009) Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 360:2191-2201
8. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS (2005) Coronary stent restenosis in patients treated with cilostazol. Circulation 112:2826-2832
9. Dzau VJ, Braun-Dullaeus RC, Sedding DG (2002) Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8:1249-1256
10. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP (1998) Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18:1942-1947
11. Feijge MA, Ansink K, Vanschoonbeek K, Heemskerk JW (2004) Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem Pharmacol 67:1559-1567
12. Flu WJ, van Kuijk JP, Hoeks SE, Kuiper R, Schouten O, Goei D, Winkel T, van Gestel YR, Verhagen HJ, Bax JJ, Poldermans D (2009) Intima media thickness of the common carotid artery in vascular surgery patients: a predictor of postoperative cardiovascular events. Am Heart J 158:202-208
13. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G (2001) Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS). Circulation 103:1721-1726
14. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C (2008) Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 7:494-499
15. Kamal AK, Naqvi I, Husain, Khealani BA (2011) Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 19:CD008076
16. Katakami N, Kim YS, Kawamori R, Yamasaki Y (2010) The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the diabetic atherosclerosis prevention by cilostazol (DAPC) study: a randomized trial. Circulation 121:2584-2591
17. Kodama M, Yamasaki Y, Sakamoto K, Yoshioka R, Matsuhisa M, Kajimoto Y, Kosugi K, Ueda N, Hori M (2000) Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb Res 97:239-245
18. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS (2005) Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36:782-786
19. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfutzner A (2005) Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111:2525-2531
20. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K (2001) Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103:919-925
21. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115:459-467
22. Lovett JK, Coull AJ, Rothwell PM (2004) Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62:569-573
23. Meijer R, Grobee DE, Bots ML (2006) Mannheim consensus on carotid intima-media thickness: opposite and complementary points of view. Cerebrovasc Dis 21:415-416
24. Mitsuhashi N, Tanaka Y, Kubo S, Ogawa S, Hayashi C, Uchino H, Shimizu T, Watada H, Kawasumi M, Onuma T, Kawamori R (2004) Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. Endocr J 51:545-550
25. Nakamura N, Hamazaki T, Johkaji H, Minami S, Yamazaki K, Satoh A, Sawazaki S, Urakaze M, Kobayashi M, Osawa H, Yamabe H, Okomura K (2003) Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. Clin Exp Med 2:180-184
26. Riccioni G (2009) Statins and carotid intima-media thickness reduction: an up-to-date review. Curr Med Chem 16:1799-1805
27. Rosenbaum PR (1995) Observational studies. Springer, New York
28. Shinoda-Tagawa T, Yamasaki Y, Yoshida S, Kajimoto Y, Tsujino T, Hakui N, Matsumoto M, Hori M (2002) A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia 45:188-194
29. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC (2004) Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24:930-934
30. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS (2008) Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 21:93-111 (quiz 189-190)
31. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M (2009) Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 361:2113-2122
32. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, Ebrahim S, Fatar M, Hernandez-Hernandez R, Kownator S, Prati P, Rundek T, Taylor A, Bornstein N, Csiba L, Vicaut E, Woo KS, Zannad F (2004) Mannheim intima-media thickness consensus. Cerebrovasc Dis 18:346-349
33. Tsivgoulis G, Vemmos K, Papamichael C, Spengos K, Manios E, Stamatelopoulos K, Vassilopoulos D, Zakopoulos N (2006) Common carotid artery intima-media thickness and the risk of stroke recurrence. Stroke 37:1913-1916
34. Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, Okabe T, Nomura M, Inoguchi T, Nawata H (2006) Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, Intimascope. Am J Hypertens 19:1206-1212